Cooper Companies Inc (NYSE:COO) – Analysts at Jefferies Financial Group cut their Q1 2020 earnings per share estimates for shares of Cooper Companies in a note issued to investors on Thursday, December 5th. Jefferies Financial Group analyst A. Petrone now forecasts that the medical device company will post earnings of $2.73 per share for the quarter, down from their previous estimate of $2.95. Jefferies Financial Group has a “In-Line” rating and a $330.00 price objective on the stock. Jefferies Financial Group also issued estimates for Cooper Companies’ Q2 2020 earnings at $3.07 EPS, Q4 2020 earnings at $3.54 EPS, FY2020 earnings at $12.78 EPS, FY2021 earnings at $14.08 EPS and FY2023 earnings at $16.95 EPS.
Cooper Companies (NYSE:COO) last issued its quarterly earnings data on Thursday, December 5th. The medical device company reported $3.30 EPS for the quarter, beating the consensus estimate of $3.27 by $0.03. The firm had revenue of $691.60 million during the quarter, compared to the consensus estimate of $683.83 million. Cooper Companies had a net margin of 17.59% and a return on equity of 17.38%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.87 earnings per share.
Shares of NYSE:COO opened at $302.26 on Monday. Cooper Companies has a 1 year low of $228.65 and a 1 year high of $344.32. The company has a market cap of $15.23 billion, a PE ratio of 24.47, a P/E/G ratio of 2.23 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.05 and a quick ratio of 0.59. The stock’s 50-day moving average is $299.21 and its 200 day moving average is $312.26.
In other news, Director Allan E. Rubenstein sold 1,335 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $299.61, for a total value of $399,979.35. Following the completion of the transaction, the director now owns 3,591 shares of the company’s stock, valued at approximately $1,075,899.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.70% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ossiam bought a new position in Cooper Companies in the second quarter worth $25,000. Kings Point Capital Management purchased a new position in Cooper Companies during the second quarter valued at $27,000. NumerixS Investment Technologies Inc bought a new stake in shares of Cooper Companies during the 2nd quarter valued at $34,000. Flagship Harbor Advisors LLC boosted its holdings in shares of Cooper Companies by 100.0% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 156 shares of the medical device company’s stock valued at $46,000 after buying an additional 78 shares in the last quarter. Finally, CSat Investment Advisory L.P. grew its position in shares of Cooper Companies by 105.6% in the 2nd quarter. CSat Investment Advisory L.P. now owns 148 shares of the medical device company’s stock worth $50,000 after buying an additional 76 shares during the period. Institutional investors own 95.35% of the company’s stock.
Cooper Companies Company Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Further Reading: What is quantitative easing?
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.